ResMed's ASX-quoted CDIs increase in September

ResMed Inc. announced an increase in its CHESS Depositary Interests (CDIs) quoted on the ASX for the month ending September 2025. The total number of quoted CDIs rose to 582,359,630, reflecting a net increase of 3,066,120 from the previous month’s total of 579,293,510. This change is attributed to net transfers of securities between CDIs and Common stock quoted or held on NYSE.

The company also provided an update on securities over which CDIs have not been issued. The RMDAB class saw a decrease, with the total number of securities at month-end reaching 877,047,650, down 2,805,290 from 879,852,940 in the prior month. This decrease is due to transfers from and to CDIs quoted on ASX, the issue of new shares on the NYSE related to stock options, restricted stock units, and employee stock purchase plans under the company's Incentive Award Plan and Employee Stock Purchase Plan, as well as share repurchases on the NYSE.

Similarly, the RMDAA: Common Stock class, representing underlying common stock, experienced a decrease of 280,529 securities, moving from 87,985,294 to 87,704,765. The reasons for this change mirror those affecting the RMDAB class, including transfers from and to CDIs quoted on ASX, new share issues related to equity plans, and share repurchases on the NYSE.